Sleep Apnoea Surgical Treatment: UPPP, MMA and Modern Options

Obstructive sleep apnoea (OSA) affects 10-15% of adults; CPAP remains the gold-standard treatment. However 30-50% of patients cannot tolerate long-term CPAP or refuse it. In such patients surgical options are considered.

Surgical candidates: moderate-severe OSA (AHI≥15), CPAP intolerance (mask discomfort, claustrophobia, pressure intolerance, severe dryness), poor CPAP adherence (<4 h/night or <70% of nights), non-positional OSA, BMI<35, anatomically obvious upper-airway obstruction.

DISE (drug-induced sleep endoscopy) is the modern cornerstone of surgical planning. The patient is sedated with propofol or midazolam; once sleep-like state is achieved, a flexible endoscope inspects oropharynx, hypopharynx and laryngeal levels. Obstruction patterns are coded by VOTE: Velum (soft palate), Oropharynx (lateral walls/tonsils), Tongue base, Epiglottis. For each level severity (none/partial/complete) and pattern (anteroposterior/lateral/concentric) are recorded.

Concentric velum collapse (especially in hypoglossal stimulation candidates) is a contraindication — Inspire failure risk is high. Lateral pharyngeal wall collapse indicates lateral pharyngoplasty or expansion sphincter pharyngoplasty. Tongue-base collapse indicates genioglossus advancement, tongue RF, or midline glossectomy.

Comprehensive workup: ENT examination (tonsil size — Friedman I-IV; nasal airway; mandibular hypoplasia), maxillofacial examination, BMI, neck circumference, Mallampati score, polysomnography (AHI, ODI, lowest oxygen saturation), cardiopulmonary comorbidity assessment.

CPAP failure definition: ≥3 months of trial + proper titration + side-effect management + counselling, still non-adherent or intolerant. If a patient refuses CPAP, surgery is considered — but alternatives (BiPAP, auto-CPAP, oral appliance) should be tried first. We expand on the clinical framework in our general ENT services.

UPPP (uvulopalatopharyngoplasty) is the classical OSA surgery defined by Ikematsu (1952) and Fujita (1981). Tonsillectomy + uvula shortening + palatal arch fusion with soft palate + reshaping of lateral pharyngeal mucosa. Goal: widen the retropalatal airway.

UPPP success rates: classical 40-50% (Sher criteria); modern series with DISE guidance + appropriate selection reach 60-70%. Friedman staging predicts outcome: Friedman I (large tonsils, low Mallampati) best; Friedman III-IV (small tonsils, high Mallampati, tongue-base collapse) poor for plain UPPP.

Modified UPPP (Friedman, Cahali): mucosa-preserving approach, less postoperative pain and dysphagia, better function. Lateral pharyngoplasty: superior plication for lateral pharyngeal wall collapse. Expansion sphincter pharyngoplasty (Pang): anterior and lateral repositioning of palatopharyngeus — both lateral wall and retropalatal widening.

Complications: nasal regurgitation (common first week; persistent <5%), velopharyngeal insufficiency (transient), voice quality change (hyponasal), taste change, persistent dysphagia (<5%), bleeding, pharyngeal stenosis (rare — after aggressive resection).

Patient selection is critical: BMI<32, AHI<60, no or minimal tongue-base collapse, large tonsils + long uvula, DISE showing Velum + Oropharynx dominant. Patients meeting these benefit most from UPPP.

When UPPP alone is insufficient: add tongue-base intervention (genioglossus advancement, tongue RF) — multilevel surgery. Multilevel is done in one session; success reaches 60-80%. Planning follows the individual obstruction map.

Postoperative course: 1-2 days hospital, marked pain control 10-14 days, soft diet 2 weeks, normal activity 2-3 weeks. Full recovery 6-8 weeks. Polysomnography is repeated at 3 months to assess efficacy.

Tongue-base collapse is critical in OSA surgery — present in >50% on DISE. It is the commonest cause of UPPP-alone failure.

Genioglossus advancement: the tongue-to-mandible attachment (genioglossus tubercle) is surgically advanced — a small rectangular mandibular bone block carrying the genioglossus is moved 5-10 mm anteriorly and plate-fixated. Pros: durable tongue-base tone, comfortable postop. Complications: lower tooth root injury (<5%), infection, plate visibility.

Tongue-base RF (radiofrequency) ablation: in-office under local anaesthesia — RF probes deliver thermal damage causing fibrosis and volume reduction. Needs 2-4 sessions, modest efficacy (30-40%). Pros: minimally invasive, in-office. Cons: multiple sessions, limited efficacy.

Midline glossectomy (with TORS assistance): midline tongue-base resection via robotic daVinci transoral approach. Effective in marked tongue-base hypertrophy. Complications: taste change, transient dysphagia, bleeding (1-2 weeks postop risky — oropharyngeal vascular bed close).

Hypoglossal nerve stimulation (Inspire — Inspire Medical Systems): FDA approved 2014; the most innovative OSA surgery. Three components: hypoglossal nerve cuff (neck), chest-wall pulse generator (pacemaker-like), intercostal breath-sensing lead. During sleep, when breath is sensed the hypoglossal nerve is stimulated → tongue protrudes → upper airway opens.

Inspire indications: AHI 15-65, documented CPAP intolerance, BMI<32, NO concentric velum collapse (assessed on DISE), tongue-base or anteroposterior velum collapse dominant. After three sessions of physician titration the patient activates the device nightly themselves.

Inspire outcomes: STAR trial (2014) — 68% AHI reduction, 15% improvement in lowest oxygen saturation; 5-year follow-up shows durable efficacy. Complications: implant infection (<2%), tongue dysaesthesia/fatigue (transient, 20%), device malfunction (<5%). Device life 10-12 years (battery).

Multilevel approach is the modern standard: instead of single-level surgery, simultaneous or staged surgery at all obstruction levels identified on DISE. UPPP + genioglossus advancement + tongue-base RF combination is common — success well above single-level surgery. Step-by-step details: sleep apnoea page.

MMA (maxillomandibular advancement) is the highest-success OSA surgical procedure. Le Fort I osteotomy (maxilla) + bilateral sagittal split osteotomy (mandible) — both jaws advanced 10-12 mm. All upper-airway levels (retropalatal + retroglossal + hypopharynx) widen simultaneously.

Indications: severe OSA (AHI>30), CPAP intolerance or failure, multilevel surgery failure, mandibular hypoplasia (lateral profile), younger age, BMI<32, high motivation. Can also be considered after hypoglossal stimulation failure.

Procedure: orthognathic surgery protocol — pre-op orthodontics (usually not needed for OSA if pure advancement), 3D CT planning, virtual surgical simulation, occlusion planning. Operating time 4-6 hours, hospital stay 3-5 days, intermaxillary fixation 2-6 weeks (with modern rigid miniplate fixation, IMF is limited or none).

MMA success rate: 85-90% (highest among OSA surgeries). Mean AHI reduction 85%, marked lowest-O2 improvement; many patients reach AHI<5 (cure). Long-term follow-up (10+ years) shows durable efficacy.

Complications: lip/chin numbness transient (inferior alveolar nerve — 50% take 6 months; 5% permanent), occlusion change (usually small, correctable orthodontically), infection (<5%), malunion (rare — 1-2%), TMJ dysfunction, facial appearance change.

Facial appearance change: 10-12 mm jaw advancement → stronger chin profile, deeper naso-facial angle, smaller submental "double chin" appearance. For many patients an aesthetic benefit — most reports positive. But expectation management is essential — preoperative 3D simulation provides preview.

Who is MMA ideal for? Younger (<50), acceptable BMI (<32), mandibular hypoplasia history/profile, multilevel surgery failure, hypoglossal stimulation contraindication (concentric velum), high motivation and process tolerance.

MMA disadvantages: invasive, long recovery (3-6 months for complete facial sensation), psychological impact (facial shape change), high cost (vs CPAP or Inspire), requires experienced orthognathic team.

Polysomnography is repeated 3 months postoperatively — success assessment (AHI reduction, oxygen saturation improvement, daytime sleepiness — Epworth score), residual OSA detection.

Surgical success definition: classical Sher — ≥50% AHI reduction and AHI<20. Modern target AHI<5 (CPAP-equivalent "cure"). Partial success (50% reduction but AHI still >20): residual OSA managed with CPAP or additional surgery (e.g. adding hypoglossal stimulation).

Weight management: post-surgical weight gain returns OSA — annual BMI and waist follow-up matter. Bariatric surgery (sleeve gastrectomy, RYGB) can add value after OSA surgery; bariatric surgery alone produces OSA remission in 50-60%.

Sleep hygiene and lifestyle: limit evening alcohol (reduces muscle tone), limit sedatives/hypnotics, weight management, regular exercise, lateral sleep position — if positional OSA component.

Long-term efficacy: UPPP 5-year efficacy 30-50% (declines over time — fibrosis, weight gain, tongue-base compensation); MMA 10-year efficacy 75-85% (permanent skeletal change); hypoglossal stimulation 5-year 60-70% (battery 10-12 years, device replacement if needed).

Cardiovascular effect: successful OSA surgery yields meaningful improvement in hypertension, cardiovascular events, atrial fibrillation, stroke, daytime sleepiness, depression and quality of life. Success should be judged not by AHI alone but by clinical outcomes.

Residual OSA: patients with persistently abnormal AHI (>5-15) postoperatively can have CPAP (often tolerated at lower pressure — more open airway), oral appliance, positional therapy, weight management, further surgery (e.g. tongue-base RF, hypoglossal stimulation add).

Expectation management: surgical success is highly variable — patient-specific, anatomy, BMI, age, choice of procedure. Realistic expectation: surgery is not always a "cure"; sometimes CPAP must be added for residual OSA. Multidisciplinary team (ENT, sleep physician, maxillofacial surgeon, dietitian, psychologist) shared follow-up. Related reading: our Istanbul ENT services.